Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects.

Next Previous
Trial Profile

A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Diabetic neuropathies; Gastro-oesophageal reflux; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors AstraZeneca

Most Recent Events

  • 26 Aug 2009 Actual patient number (132) added as reported by ClinicalTrials.gov.
  • 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 08 Jul 2009 Planned number of patients changed from 40 to 60, additional lead trial investigator (Neijber A) identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top